Thrombin is a serine protease that is generated by proteolytic cleavage of its precursor, prothrombin. We previously showed that thrombin proteolyses the microtubule-associated protein tau and that phosphorylation of tau inhibits this process. To characterize further the role of thrombin in the brain, we investigated prothrombin and thrombin expression in cultured brain cells and in brains of control, Alzheimer disease (AD) and parkinsonism-dementia complex of Guam (PDCG). We show by reverse transcriptase-polymerase chain reaction that prothrombin mRNA is expressed in brain tissues, neuroblastoma cells, and cultured human astrocytes, oligodendrocytes, and microglial cells. We also show by immunohistochemistry that the proteins prothrombin and thrombin are present in brain using specific monoclonal and polyclonal antibodies for both proteins. All antibodies stained residual serum in blood vessels, as well as normal pyramidal neurons and their processes, and some astrocytes. Additionally, in AD and PDCG cases, all antibodies stained extraand intracellular neurofibrillary tangles (NFTs), senile plaques, and reactive microglial cells. The ubiquitous expression of prothrombin and thrombin in brain cells suggests that thrombin plays an important physiological role in normal brain. The accumulation of thrombin and prothrombin in NFTs supports the hypothesis that thrombin may be involved in tau proteolysis and that failure to metabolize tau may lead to its aggregation in neurodegenerative diseases.
INTRODUCTION
Thrombin is a trypsin-like serine protease that is best known for its participation in blood coagulation. It is generated by proteolytic cleavage of its precursor, prothrombin, which is produced primarily in the liver and circulates in plasma (1) .
Previous reports indicate that prothrombin mRNA is expressed in neuronal cells (2, 3) as well as in astrocytes (4), indicating a significant role for thrombin in brain. Thrombin inhibitors are also expressed in these cells. They include protease nexin-1 (5), antithrombin III (4), a1-antitrypsin (6), a2-macroglobulin (7), C1-inhibitor (8) , and thrombomodulin (9) . Thrombin receptors such as protease-activated receptor-1, -3, and -4 are also expressed (10) . There is some evidence that thrombin modifies the morphology of neurons and astrocytes, induces glial cell proliferation, and exerts protective or toxic effects on neurons (10) , indicating the possibility of complex actions in brain tissue.
Furthermore, thrombin has been reported to be present in senile plaques and in the neurofibrillary tangles (NFTs) in layer Pre-a of the entorhinal cortex of Alzheimer disease (AD) brains (11) . Recently, we reported that brain thrombin proteolyses the microtubule-associated protein tau and that phosphorylation of tau inhibits these proteolytic processes (12) .
In vitro, thrombin cleaves amyloid precursor protein, generating an amyloidogenic intermediate, which fully incorporates amyloid b peptide (13) . Thrombin also cleaves apolipoprotein E, generating a neurotoxic 22-kDa fragment (14, 15) .
To clarify further the pathophysiological role of thrombin in human brain, we have studied the expression of prothrombin mRNA and prothrombin and thrombin proteins in brains of control, AD, and parkinsonism-dementia complex of Guam (PDCG) cases, and in cultured brain cells. We show that both prothrombin and thrombin are expressed in neuronal and glial cells. Furthermore, we show that they are associated with both extra-and intracellular NFTs in AD and PDCG. These findings are consistent with the hypothesis that thrombin is involved in tau proteolysis and that its failure to proteolyse surplus tau can lead to tau aggregation in neurodegenerative diseases.
MATERIALS AND METHODS

Postmortem Human Brains
Brains from 7 controls, 9 cases with AD, and 3 with PDCG were selected from our Kinsmen Laboratory brain bank for reverse transcriptase-polymerase chain reaction and immunohistochemical studies. The age, sex, postmortem interval, brain weight, and diagnosis are given in Table 1 .
Human Neuronal Cell Lines
The human neuroblastoma SH-SY5Y cell line was a gift from Dr. R. Ross, Fordham University, New York, NY, whereas LA-N-2 cells were obtained from Dr. R. C. Seeger, Children's Hospital, Los Angeles, CA. Cells were grown in Dulbecco modified Eagle's medium-nutrient mixture F12 ham (DMEM-F12; Sigma-Aldrich, Oakville, ON, Canada) supplemented with 10% fetal bovine serum (FBS; GIBCO BRL, Life Technologies, Burlington, ON, Canada) and 50 mg/mL gentamicin sulfate. Incubation was carried out in a humidified 5% CO 2 /95% air atmosphere at 37°C. Retinoic acid-differentiated SH-SY5Y cultures were prepared as previously described (16, 17) by adding 8 3 10 5 cells to 60-mm tissue culture dishes in DMEM-F12 supplemented with 5% FBS. Cell cultures were analyzed for prothrombin mRNA after 2-to 24-hour incubation.
Primary Cultures of Human Glial Cells
Human microglial, astrocytic, and oligodendroglial cells were isolated from surgically resected temporal lobe tissues. The authors thank Dr. J. Maguire, Department of Pathology and Laboratory Medicine, Vancouver General Hospital, for providing the surgical specimens. Isolation protocols described by De Groot et al (18, 19) were used with minor modifications (20, 21) . Before their mRNAs were extracted, microglial and astrocytic cells were grown for 7 days, whereas oligodendroglial cells were grown for 1 to 7 days as previously described (20, 21) .
RNA Isolation and cDNA Synthesis by Reverse Transcription
Total RNA from brains and cultured cells was isolated by the acid guanidinium thiocyanate-phenol-chloroform method. Two micrograms of the resultant RNA extract was then used to prepare cDNA. RNA was treated with 10 U of DNase I (Invitrogen Life Technologies, Burlington, ON, Canada) for 60 minutes at 37°C in 25 mL of 13 reverse transcription buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl 2 ) containing 40 U of RNase inhibitor (Amersham Biosciences, Baie d'Urfé, PQ, Canada) and 1 mM dithiothreitol (DTT) followed by incubation at 85°C for 5 minutes to inactivate the enzyme. Reverse transcription was performed at 42°C for 90 minutes in 50 mL of the following mixture: 13 reverse transcription buffer containing 2 mg of RNA, 5 mM DTT, 0.2 mg random hexamer primers (Amersham Biosciences), 1 mM deoxynucleotides (Invitrogen Life Technologies), 40 U of RNase inhibitor, and 400 U of SuperScript II reverse transcriptase (Invitrogen Life Technologies). At the end of the incubation period, the enzyme was inactivated by heating at 65°C for 10 minutes (22) .
Polymerase Chain Reaction
One microliter of the transcription reaction was amplified for prothrombin by nested polymerase chain reaction (PCR). The PCR reaction was carried out in a 25-mL mixture containing 13 GeneAmp PCR buffer II (Applied Biosystems, Streetsville, ON, Canada), 1.25 U of AmpliTaq Gold DNA polymerase (Applied Biosystems), 2 mM MgCl 2 (Applied Biosystems), 200 mM dNTPs (Invitrogen Life Technologies), and 0.5 mM of each primer. The amplification program consisted of an initial denaturation step at 94°C, which was extended to 9 minutes to activate AmpliTaq Gold enzyme. This was followed by an annealing step at 55°C for 1 minute and an initial synthesis step at 72°C for 3 minutes. The remaining cycles were 1 minute at 94°C, 1 minute at 55°C, and 1 minute at 72°C. The number of cycles performed was 25 for both primary and secondary nested PCR. The primers used for the initial PCR were forward, 5# ATGAGGAGGGCGTGTGGTGCTATGT 3# and reverse, 5# CCGTCGATGTAGGATTCCAGGAGCT 3#. The primers for the second nested PCR were forward, 5# CTATTGTGAG-GAGGCCGTGGAGG 3# and reverse, 5# AACAGAGGTCG-CAGCCCACAGTC 3#. After amplification, PCR products were separated on a 6% polyacrylamide gel and visualized by incubation for 10 minutes in a solution containing 10 ng/mL of ethidium bromide. Polaroid photographs of the gels were taken. The predicted size of the PCR product is 159 bp. Restriction digest analysis of the product by Dde I (GIBCO BRL, Life Technologies) resulted in 2 fragments corresponding to the predicted sizes of 107 and 52 bp.
Immunohistochemical Analysis
Brain tissues from the bank had originally been fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 2 days and then transferred to a solution of 15% sucrose in 0.01 M phosphate-buffered saline (PBS), pH 7.4, for long-term maintenance. Sections of the hippocampus and the frontal and temporal regions were cut on a freezing microtome at 30 mm. The sections were immunostained with 4 well-characterized commercial antibodies: a monoclonal (AHP-5013; Haematologic Technologies, Inc., Essex Junction, VT) and a polyclonal (A0325; DakoCytomation, Glostrup, Denmark) specific for human prothrombin; and a monoclonal (EST-7; American Diagnostica, Inc., Stamford, CT), and a polyclonal (4702; American Diagnostica, Inc.) specific for human thrombin ( Table 2) . Both antithrombin antibodies, 4702 and EST-7, recognize thrombin but do not recognize prothrombin (11, 12, 23) . Both antiprothrombin antibodies, A0325 and AHP-5013, recognize prothrombin and prethrombin-1 (12) . AHP-5013 does not recognize thrombin while A0325 may recognize thrombin fragments.
For immunostaining, the avidin-biotin-horseradish peroxidase (HRP) technique was used. To eliminate endogenous peroxidase activity, the sections were pretreated with 0.3% H 2 O 2 in PBS for 30 minutes. The primary antibody was diluted in PBS containing 0.1% Triton-X100 (PBST) and 1% normal serum from the species in which the secondary antibody was raised. After incubation with the specific primary antibody for 48 hours at 4°C, the sections were treated with the appropriate biotinylated secondary antibody (Vector Laboratories, Burlingame, CA; diluted 1:1000) for 2 hours at room temperature. The sections were then washed in PBST and incubated for 1 hour at room temperature with avidin-biotinylated HRP complex (ABCElite; Vector Laboratories) following instructions provided by the manufacturer. Peroxidase labeling was detected by incubation with a solution containing 0.01% 3, 3#-diaminobenzidine (DAB, Sigma), 0.6% nickel ammonium sulfate, 0.05 M imidazole, and 0.00015% H 2 O 2 . A dark purple reaction appeared after 7 to 25 minutes. During that time, control positive sections were monitored under a microscope for efficiency of immunostaining. In some sections, the use of 0.6% nickel ammonium sulfate was omitted to obtain a brown immunoreaction with DAB. Some sections were counterstained with neutral red or hematoxylin. The sections were then washed in distilled water and mounted on glass slides. After dehydration, the sections were transferred to xylene and coverslipped with Entellan (Merck, Darmstadt, Germany). Control sections in which the immunoreaction was performed in the same way, but with omission of the primary antibody, were always performed and were used as negative controls. (Fig. 2E ) or antimouse IgG (Fig. 2F) . These results suggest that the staining is not the result of endogenous peroxidase. Figure 3 illustrates positive staining of normal cortical pyramidal neurons with all 4 antibodies. Such positive staining was observed in all areas examined, including frontal, temporal, and entorhinal cortices, and the hippocampus. Perikarya, dendritic trees, and axons were all immunostained. Some labeled axons could be followed for considerable distances. Figure 4 illustrates immunostaining of subcortical white matter in control cases showing positive axons and some positive astrocytes. Figure 5 illustrates immunostaining of pathologic tissue. Again, no differences in immunostaining were found between the 2 prothrombin and 2 thrombin antibodies. They all detected normal appearing pyramidal neurons and their processes like in control cases (Fig. 5A, B ) in all cortical areas examined (frontal, temporal, parietal, and precentral regions). They also detected NFTs in all AD and PDCG cases. In both AD and PDCG, the hippocampus and entorhinal cortex are known to be more severely affected with a large number of extracellular NFTs in contrast to other cortical areas (e.g. frontal, parietal, temporal) where the majority of NFTs are intracellular. In the sections of the hippocampus counterstained with neutral red to reveal cell nuclei, many prothrombin-and thrombin-positive fibrillary structures do not have neuronal nuclei and show the wispy appearance, suggesting that they are extracellular NFT (Fig. 5C,  D) . The presence of neuronal nuclei in tangle-bearing neurons in the inferior temporal cortex of the same PDCG case, and an AD case indicates that intracellular NFTs are also immunostained ( Fig. 5E-H) . Senile plaques (Fig. 5I, J) and reactive microglial cells (Fig. 5I , J, arrows) were also immunopositive in AD cases. With respect to the intensity of the immunoreaction of prothrombin and thrombin, the extracellular NFTs showed the strongest reaction followed by the intracellular NFTs and normal-appearing neurons.
RESULTS
DISCUSSION
Prothrombin mRNA has previously been detected in SK-N-SH neuroblastoma cells by reverse transcriptase-polymerase chain reaction (2) and in rat brain neurons by in situ hybridization (2, 3) . In the present study, in addition to confirming prothrombin mRNA expression in neurons, we have found prothrombin mRNA to be expressed in primary cultures of human astrocytes, oligodendrocytes, and microglial cells. In addition, we have observed the expression of both prothrombin and thrombin proteins in cell bodies, axons, and dendrites of normal pyramidal neurons and occasional astrocytes by immunohistochemistry. One of the significant findings in this study is the presence of thrombin and prothrombin in both extra-and intracellular NFTs in brains of patients with AD and those with PDCG, extending our previous observations regarding thrombin accumulation in AD brains (11). We also previously reported that brain thrombin degrades tau and that phosphorylation of tau inhibits these degradation processes (12) . Taken together, these findings suggest that thrombin is involved in tau degradation and its failure can lead to tau aggregation and NFT formation.
Wagner et al reported that in AD brains, there is a reduction of free protease nexin-1 and an increase of a protease nexin-1-containing complex that comigrates with the protease nexin-1-thrombin complex, indicating that a specific thrombin inhibition is taking place (24) . Levels of protease nexin-1 are reduced in tau-positive dystrophic neurites of AD hippocampus (25) . Thus, alterations in the interactions between thrombin and protease nexin-1 may be one of the factors that causes a failure of tau degradation by thrombin, resulting in tau aggregation.
In addition to neuronal cells, we have shown the expression of prothrombin mRNA in cultured human astrocytes, oligodendrocytes, and microglial cells. We have identified the proteins of prothrombin and thrombin in astrocytes in the white matter of patients with AD and controls and in reactive microglial cells in the core area of senile plaques in AD. Deschepper et al reported that primary cultured human astrocytes contain prothrombin mRNA and secrete a thrombinlike protein that makes complexes with antithrombin III (4). Giuntoli and Retzinger reported that phorbol ester-treated THP-1 cells, which assume the macrophage phenotype, express concurrently prothrombin mRNA, antigenic prothrombin and thrombin, and thrombin activity (26) . These reports are consistent with our results showing the expression of prothrombin and thrombin in astrocytes and microglial cells. The proteins were not observed in oligodendrocytes, although prothrombin mRNA was present. The reason for this discrepancy is not understood but may reflect the fact that expression of mRNA does not necessarily translate to accumulation of protein within the cell.
In conclusion, the ubiquitous expression of prothrombin and thrombin in neurons and glial cells supports the hypothesis that thrombin has important physiological functions in human brain, although its biologic role in each cell type needs to be further investigated. In neurons, thrombin may be involved in proteolysis of cytoskeletal proteins such as tau and its failure may result in aggregation of these proteins. The results of the present study, which showed the localization of thrombin and prothrombin in axons and dendrites as well as in the neuronal cytoplasm, further support this notion.
